Page last updated: 2024-12-10

diosmin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281613
CHEMBL ID231884
CHEBI ID4631
SCHEMBL ID120870
MeSH IDM0006496

Synonyms (117)

Synonym
SMP1_000183
diosmin ,
C10039
diosmetin 7-o-rutinoside
520-27-4
5-hydroxy-2-(3-hydroxy-4-methoxy-phenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromen-4-one
4h-1-benzopyran-4-one, 7-((6-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-
NCGC00095022-01
MLS001304032
smr000718616
chebi:4631 ,
dioven
flebosten
nsc-758417
litosmil
flebaven
diosmetin 7-rutinoside
CHEMBL231884
flebavena
tovene
insuven
ven-detrex
varinon
diosven
hemerven
flebosmil
diosmin (inn)
D07858
daflon (tn)
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
daflon
venosmine
barosmin
resin, buchu
buchu resin
4h-1-benzopyran-4-one, 7-((6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
3',5,7-trihydroxy-4'-methoxyflavone 7-rutinoside
BCP9000612
tox21_111392
dtxcid2025892
dtxsid4045892 ,
cas-520-27-4
HMS2233P16
AKOS015969767
BCP0726000067
rioven
diosmine [inn-french]
3',5,7-trihydroxy-4'-methoxyflavone-7-(6-o-(-deoxy-alpha-l-mannopyraonsyl)-beta-d-glucopyranoside
diosmetin-7-o-rutinoside
3',5-dihydroxy-4'-methoxy-4-oxo-4h-chromen-7-ylrutosid
diosmine
veno-v
diosmil
diosminum
diosminum [inn-latin]
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((6-o-alpha-l-rhamnopyranosyl-beta-d-glycopyranosyl)oxy)-4-chromenon
7-((6-o-(6-deoxy-ga-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one
ccris 7915
unii-7qm776wj5n
3',5-dihydroxy-4'-methoxy-4-oxo-4h-chromen-7-ylrutosid [iupac]
diosmin [inn:ban]
einecs 208-289-7
diosmin [inn-spanish]
diovenor
se 4601
7qm776wj5n ,
nsc 758417
BP-12422
diosmin [inn]
diosmin [ep monograph]
diosmin [mi]
diosmine [inci]
7-((6-o-(6-deoxy-ga-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one
diosmin [dsc]
diosmin [mart.]
28680-33-3
diosmin [who-dd]
diosmin [usp-rs]
S2292
diosmin (8)
bdbm153267
CCG-208570
SCHEMBL120870
tox21_111392_1
NCGC00344564-01
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(o6-alpha-l-rhamnopyranosyl-beta-d-glucopyranosyloxy)chromen-4-one
3',5,7-trihydroxy-4'-methoxy flavone-7-rutinoside
3',5,7-trihydroxy-4'-methoxyflavone-7-rutinoside
3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucoside
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-4h-1-benzopyran-7-yl 6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside
4h-1-benzopyran-4-one, 7-[[6-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-
diosimin
DB08995
SR-01000799147-5
SR-01000799147-4
sr-01000799147
SR-01000799147-6
diosmin, analytical standard
diosmin, united states pharmacopeia (usp) reference standard
diosmin for system suitability, european pharmacopoeia (ep) reference standard
diosmin, european pharmacopoeia (ep) reference standard
HMS3713L08
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(((2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)methyl)tetrahydro-2h-pyran-2-yloxy)-4h-chromen-4-one
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
Q2607865
AS-13224
4h-1-benzopyran-4-one,7-[[6-o-(6-deoxy-a-l-mannopyranosyl)-b-d-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-
EN300-18388399
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one
GLXC-13353
diosmina
3',5-dihydroxy-4'-methoxy-4-oxo-4h-chromen-7-ylrutosid (iupac)
diosmin (usp-rs)
diosmin (ep monograph)
c05ca03
diosmin (mart.)

Research Excerpts

Overview

Diosmin is a flavone glycoside derived from hesperidin, a flavanone abundantly found in citrus fruits. Diosmin (Dio) is a safe drug that is available for clinical use for vascular disorders.

ExcerptReferenceRelevance
"Diosmin is a citrus flavonoid with antioxidant and anti-inflammatory activities."( Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
Artero, NA; Borghi, SM; Casagrande, R; Fattori, V; Ferraz, CR; Rasquel-Oliveira, FS; Verri, WA, 2020
)
2.72
"Diosmin is a flavone glycoside derived from hesperidin, a flavanone abundantly found in citrus fruits."( Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review.
El-Demerdash, E; Elsherbiny, DA; Gerges, SH; Wahdan, SA, 2022
)
1.79
"Diosmin is an antioxidant flavonoid found mostly in citrus fruits."( Investigation of the efficacy of diosmin against organ damage caused by bendiocarb in male Wistar albino rats.
Bahar, O; Eraslan, G, 2023
)
1.91
"Diosmin is a flavonoid with promising anti-inflammatory and antioxidant properties. "( Diosmin nanocrystal gel alleviates imiquimod-induced psoriasis in rats via modulating TLR7,8/NF-κB/micro RNA-31, AKT/mTOR/P70S6K milieu, and Tregs/Th17 balance.
Abdallah, OY; Atia, NM; El-Aal, SAA; Ibrahim, SSA; Reda, AM; Shahine, Y; Sheta, E, 2023
)
3.8
"Diosmin is a naturally occurring flavonoid glycoside that has antioxidant, anti-inflammatory, and antifibrotic activities."( Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach.
Li, XL; Shi, R; Wang, DG; Wang, ZJ; Zhao, WM; Zhu, Y, 2023
)
1.88
"Diosmin is a type of flavonoid found mainly in citrus fruits."( The effect of diosmin against liver damage caused by cadmium in rats.
Ağır, MS; Eraslan, G, 2019
)
1.6
"Diosmin is a natural compound with a wide range of biological activity, e.g., it improves lymphatic drainage, supports microcirculation, and increases venous tone, and venous elasticity, hence, it is applied in the pharmacotherapy of chronic venous disorders (CVD). "( Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis.
Bogucka-Kocka, A; Bogucki, J; Feldo, M; Kęsik, J; Kocki, J; Sowa, I; Wójciak-Kosior, M; Zubilewicz, T, 2019
)
2.36
"Diosmin (Dio) is a safe drug that is available for clinical use for vascular disorders."( Diosmin ameliorative effects on oxidative stress and fibrosis in paraquat-induced lung injury in mice.
Khodayar, MJ; Mansouri, E; Mirzaee, S; Shirani, M; Zeinvand-Lorestani, M, 2019
)
2.68
"Diosmin is a citrus flavone that possesses antioxidant, anti-inflammatory, antiproliferative, and anticancer activities, so based on these properties of diosmin, we decided to evaluate its effect on testosterone propionate (TP)-induced BPH."( Protective role of diosmin against testosterone propionate-induced prostatic hyperplasia in Wistar rats: Plausible role of oxidative stress and inflammation.
Afzal, SM; Barnwal, P; Islam, J; Rashid, S; Shahid, A; Sultana, S; Vafa, A, 2020
)
1.61
"Diosmin is a flavone glycoside clinically used as the main component of Daflon for the treatment of venous diseases. "( Diosmin induces caspase-dependent apoptosis in human glioblastoma cells.
Ascari, LM; Cordeiro, Y; Faria, BM; Romão, LF; Soares, AG; Soares, JM; Souza, JM, 2019
)
3.4
"Diosmin is a flavonoid obtained from the citrus fruits of the plants. "( Exploration of Diosmin to Control Diabetes and Its Complications-an In Vitro and In Silico Approach.
Dubey, K; Dubey, R; Gupta, A; Gupta, R, 2021
)
2.42
"Diosmin is a famous natural flavonoid for treating chronic venous insufficiency and varicose veins. "( Metabolism and pharmacological activities of the natural health-benefiting compound diosmin.
Chen, Z; Li, L; Liu, H; Shi, W; Wu, L; Zhang, R; Zheng, Y, 2020
)
2.23
"Diosmin (DS) is a flavonoid with a wide range of bioactivities."( Targeting KEAP1/Nrf2, AKT, and PPAR-γ signals as a potential protective mechanism of diosmin against gentamicin-induced nephrotoxicity.
Ali, FEM; El-Bahrawy, AH; Hassanein, EHM; Omar, ZMM; Sayed, AM, 2021
)
1.57
"Diosmin is a natural flavone glycoside (bioflavonoid) found in fruits and plants with several pharmacological activities. "( Dual modulatory effects of diosmin on calcium oxalate kidney stone formation processes: Crystallization, growth, aggregation, crystal-cell adhesion, internalization into renal tubular cells, and invasion through extracellular matrix.
Khamchun, S; Thongboonkerd, V; Yoodee, S, 2021
)
2.36
"Diosmin is a nutrient that is widely contained in citrus and that has been indicated to improve glucose metabolism in diabetic disorders. "( Diosmin, a Citrus Nutrient, Activates Imidazoline Receptors to Alleviate Blood Glucose and Lipids in Type 1-Like Diabetic Rats.
Cheng, JT; Hsu, CC; Lin, MH; Wu, MC, 2017
)
3.34
"Diosmin is a flavonoid commonly found in citrus fruits, largely used as adjuvant treatment for circulatory disorders, including chronic venous insufficiency (CVI) and hemorrhoids. "( Comparative Bioavailability of Two Diosmin Formulations after Oral Administration to Healthy Volunteers.
Chandradhara, D; De Tommasi, N; Russo, R, 2018
)
2.2
"Diosmin is a natural flavonoid applied in vascular system disorders, especially in chronic venous insufficiency (CVI), and it plays a significant part in the alleviation of CVI symptoms."( Influence of Diosmin Treatment on the Level of Oxidative Stress Markers in Patients with Chronic Venous Insufficiency.
Aszyk, J; Bogucka-Kocka, A; Bogucki, J; Feldo, M; Kot-Waśik, A; Sowa, I; Wójciak-Kosior, M; Woźniak, M; Zubilewicz, T, 2018
)
1.57
"Diosmin is an unsaturated flavonoid glycoside, presents in citrus fruits. "( Diosmin suppresses the proinflammatory mediators in lipopolysaccharide-induced RAW264.7 macrophages via NF-κB and MAPKs signal pathways.
Berkoz, M, 2019
)
3.4
"Diosmin (DM) is a naturally occurring flavone and has been found to possess numerous therapeutic properties. "( Diosmin protects against trichloroethylene-induced renal injury in Wistar rats: plausible role of p53, Bax and caspases.
Ali, F; Hamiza, OO; Khan, R; Lateef, A; Quaiyoom Khan, A; Rehman, MU; Sultana, S; Tahir, M, 2013
)
3.28
"Diosmin is a flavone glycoside, having anti-inflammatory and anti-cancer properties."( Diosmin protects against ethanol-induced hepatic injury via alleviation of inflammation and regulation of TNF-α and NF-κB activation.
Ali, F; Khan, AQ; Khan, R; Lateef, A; O'Hamiza, O; Qamar, W; Rehman, MU; Sultana, S; Tahir, M, 2013
)
2.55
"Diosmin is a naturally occurring flavone glycoside used in the treatment of venous diseases. "( Diosmin--isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use.
Bogucka-Kocka, A; Feldo, M; Kockic, J; Szewczyk, K; Woźniak, M, 2013
)
3.28
"Diosmin (DSN) is an outstanding phlebotonic flavonoid with a tolerable potential for the treatment of colon and hepatocellular carcinoma. "( Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation.
Abdallah, OY; Elnaggar, YS; Freag, MS, 2013
)
2.07
"Diosmin is a glycosylated polyphenolic compound, commonly found in fruits and vegetables, which is utilized for the pharmacological formulation of some drugs. "( Diosmin binding to human serum albumin and its preventive action against degradation due to oxidative injuries.
Barreca, D; Bellocco, E; Bruno, G; Laganà, G; Magazù, S, 2013
)
3.28
"Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs. "( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
2.26
"Diosmin (DIO) is a natural citrus flavone with remarkable antioxidant and anti-inflammatory features that underlay its protection against cardiac, hepatic and renal injuries."( Diosmin protects against ethanol-induced gastric injury in rats: novel anti-ulcer actions.
Arab, HH; Arafa, el-SA; Maghrabi, IA; Omar, HA; Salama, SA, 2015
)
2.58
"Diosmin is a naturally occurring flavonoid present in citrus fruits and other plants belonging to the Rutaceae family. "( Pharmacokinetic Profile of µSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats.
Ciccone, M; Mancinelli, A; Pisano, C; Russo, R; Severino, L; Terruzzi, F, 2015
)
2.1

Effects

Diosmin has a potential multi- component, multi-target, and multi-pathway molecular mechanism of action in the treatment of renal fibrosis. Diosmin is widely used to treat patients with vascular pain for its potent anti-inflammatory and analgesic effects.

ExcerptReferenceRelevance
"Diosmin has a potential multi-component, multi-target, and multi-pathway molecular mechanism of action in the treatment of renal fibrosis. "( Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach.
Li, XL; Shi, R; Wang, DG; Wang, ZJ; Zhao, WM; Zhu, Y, 2023
)
2.6
"Diosmin has been reported to treat diabetes, but its role in diabetic nephropathy (DN) remains unclear. "( Diosmin mitigates high glucose-induced endoplasmic reticulum stress through PI3K/AKT pathway in HK-2 cells.
Chen, L; Ci, H; Deng, J; Hua, Z; Wang, G; Zheng, C, 2022
)
3.61
"Diosmin has a potential multi-component, multi-target, and multi-pathway molecular mechanism of action in the treatment of renal fibrosis. "( Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach.
Li, XL; Shi, R; Wang, DG; Wang, ZJ; Zhao, WM; Zhu, Y, 2023
)
2.6
"Diosmin has also been used for the treatment of various diseases including diabetes mellitus and Alzheimer's disease."( Protective effect of Diosmin against benzo(a)pyrene-induced lung injury in Swiss Albino Mice.
Afzal, SM; Islam, J; Shree, A; Sultana, S; Vafa, A, 2020
)
1.6
"Diosmin has blood lipid lowering activities, antioxidant activity, enhances venous tone and microcirculation, protects capillaries, mainly by reducing systemic oxidative stress."( Exploration of Diosmin to Control Diabetes and Its Complications-an In Vitro and In Silico Approach.
Dubey, K; Dubey, R; Gupta, A; Gupta, R, 2021
)
1.7
"Diosmin has been commonly utilized to treat various diseases both traditionally and now clinically."( Diosmin Regulates Oxidative Stress and Inflammatory Marker Levels in N-Methyl-N-Nitrosourea-Induced Gastric Carcinogenesis in Rats.
Liu, W; Zhang, J; Zhao, Y, 2020
)
2.72
"Diosmin has been widely used to treat patients with vascular pain for its potent anti-inflammatory and analgesic effects. "( A Randomized Controlled Trial Evaluating the Effects of Diosmin in the Treatment of Radicular Pain.
Cao, Y; Fang, X; Li, Y; Shi, H; Wang, Y; Ye, L, 2017
)
2.14
"Diosmin has shown beneficial effect in preventing the progression of early diabetic neuropathy in rats."( Protective effect of diosmin against diabetic neuropathy in experimental rats.
Bansal, MK; Dalvi, R; Jain, D; Somani, R; Upganlawar, A, 2014
)
2.16

Actions

Diosmin did not inhibit GBM95 and GBM02 cell proliferation. It caused DNA fragmentation and increased cleaved caspase-3 expression in these cells. Diosmin does not cause venous contraction or potentiate the venotonic effects of endogenous venoconstrictors or escin ex vivo.

ExcerptReferenceRelevance
"Diosmin did not inhibit GBM95 and GBM02 cell proliferation, but it caused DNA fragmentation, as verified by the TUNEL assay, and increased cleaved caspase-3 expression in these cells."( Diosmin induces caspase-dependent apoptosis in human glioblastoma cells.
Ascari, LM; Cordeiro, Y; Faria, BM; Romão, LF; Soares, AG; Soares, JM; Souza, JM, 2019
)
2.68
"Diosmin did not enhance the IVC contraction to PHE, AngII, or escin, but enhanced the contractile response to KCl (24-51 mM)."( Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.
Khalil, RA; Raffetto, JD, 2011
)
1.09
"Diosmin does not cause venous contraction or potentiate the venotonic effects of endogenous venoconstrictors or escin ex vivo, and its use as venotonic may need to be further evaluated."( Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.
Khalil, RA; Raffetto, JD, 2011
)
1.09

Treatment

Diosmin pretreatment significantly enhanced AUC, C(max) and t1/2 with a concomitant reduction in CL/f. Pretreatment with diosmin revealed preventive effects on LVH, and all the above menti.

ExcerptReferenceRelevance
"Diosmin treatment, however, leads to decreased peroxidation of lipids, increased antioxidant proteins as well decrease in the level of CEA and NSE."( Chemopreventive potential of Diosmin against benzo[a]pyrene induced lung carcinogenesis in Swiss Albino mice.
Islam, J; Khan, HA; Shree, A; Sultana, S, 2022
)
1.73
"Diosmin treatment inhibited the protein and mRNA levels of CASP3, MMP9, ANXA5, and HSP90AA1."( Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach.
Li, XL; Shi, R; Wang, DG; Wang, ZJ; Zhao, WM; Zhu, Y, 2023
)
1.88
"Diosmin treatment in diabetic rats lowered elevated blood glucose levels, homeostatic model assessment for insulin resistance, cardiac creatine kinase and lactate dehydrogenase enzymes, cardiac malondialdehyde and nitric oxide. "( The Potential Protective Effects of Diosmin on Streptozotocin-Induced Diabetic Cardiomyopathy in Rats.
Abo-Salem, OM; Ali, TM; El Askary, A; El Esawy, BH, 2020
)
2.28
"Diosmin treatment also increased epidermal thickness in the HSE model."( Diosmin restores the skin barrier by targeting the aryl hydrocarbon receptor in atopic dermatitis.
Jung, CH; Lee, J; Song, KM, 2021
)
2.79
"Diosmin treatment ameliorated the MTX-induced elevation of serum alkaline phosphatase, aminotransferases, urea, creatinine, lactate dehydrogenase, and creatine kinases as well as plasma proinflammatory cytokines (interleukin-1-beta, interleukin-6, and tumor necrosis factor-alpha)."( Diosmin Attenuates Methotrexate-Induced Hepatic, Renal, and Cardiac Injury: A Biochemical and Histopathological Study in Mice.
Abdel-Daim, MM; Abushouk, AI; Al-Quraishy, SA; Dkhil, MA; Khalifa, HA, 2017
)
2.62
"Diosmin pretreatment showed significant preventive effects on all the biochemical parameters, and the structure of mitochondria was evaluated."( Diosmin Prevents Isoproterenol-Induced Heart Mitochondrial Oxidative Stress in Rats.
John, B; Sharmila Queenthy, S; Stanely Mainzen Prince, P, 2018
)
2.64
"Diosmin treated A431 cells also revealed multiple DNA fragments than the untreated cells."( Diosmin reduces cell viability of A431 skin cancer cells through apoptotic induction.
Buddhan, R; Manoharan, S,
)
2.3
"Diosmin treatment showed a substantial reduction in T cell (CD4(+) and CD8(+)) receptors and pro-inflammatory (IL-2(+) and IL-17(+)) cytokines in whole blood."( Diosmin downregulates the expression of T cell receptors, pro-inflammatory cytokines and NF-κB activation against LPS-induced acute lung injury in mice.
Ahmad, SF; Al Hoshani, AR; Al-Harbi, MM; Al-Harbi, NO; Ansari, MA; Anwer, MK; Attia, SM; Imam, F; Iqbal, M; Zoheir, KM, 2015
)
2.58
"Diosmin treatment produces significant reduction in the blood glucose and plasma insulin level and increases the body weight when compared with diabetic rats."( Diosmin Modulates the NF-kB Signal Transduction Pathways and Downregulation of Various Oxidative Stress Markers in Alloxan-Induced Diabetic Nephropathy.
Ahmed, A; Ahmed, S; Bolshette, N; Borgohain, M; Chowdhury, L; Kwatra, M; Lahkar, M; Mundhe, N, 2016
)
2.6
"Diosmin pretreatment significantly enhanced AUC, C(max) and t1/2 with a concomitant reduction in CL/f."( Influence of diosmin pretreatment on the pharmacokinetics of chlorzoxazone in healthy male volunteers.
Krishna, DR; Nagulu, M; Rajnarayana, K; Srinivas, M; Venkatesham, A, 2008
)
1.44
"In diosmin-treated veins incubated in 0 Ca(2+) Krebs, addition of extracellular CaCl(2) caused minimal contraction."( Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.
Khalil, RA; Raffetto, JD, 2011
)
0.88
"Diosmin pretreatment significantly altered the metabolism of metronidazole, as demonstrated by changes in plasma pharmacokinetics as well as by urinary recovery of both parent drug and its major metabolites. "( Diosmin pretreatment affects bioavailability of metronidazole.
Krishna, DR; Rajnarayana, K; Reddy, MS, 2003
)
3.2
"Diosmin pretreatment significantly enhanced AUC, C(max) and t1/2 with a concomitant reduction in CL/f."( Bioavailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers.
Krishna, DR; Rajnarayana, K; Venkatesham, A, 2007
)
1.3
"With diosmin treatment, only thiobarbituric acid reactive substances significantly decreased in group 4, whereas vitamin A level increased."( In vivo effect of diosmin on carrageenan and CCl4-induced lipid peroxidation in rat liver microsomes.
Clerc, M; Melin, AM; Perromat, A, 1996
)
1.08
"Diosmin treatment opposed the rise in RBC rigidity evoked by the gavage and induced a dose-dependent decrease of the RBC membrane cholesterol over phospholipid ratio."( Effect of diosmin upon red blood cell deformability and osmotic fragility. Relationship with lipid content.
Garnier, M; Perret, G; Pilardeau, P; Rolland, Y; Uzzan, B; Vassy, R; Vaysse, J, 1988
)
1.4
"Treatment with diosmin demonstrated multiple beneficial effects as it significantly ameliorated histopathological NASH findings, lowered TNF-α, interleukin-6, and malondialdehyde levels, improved lipid and glucose metabolism, and lowered hepatic TGF-β, α-SMA, and collagen content compared to untreated rats."( Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats.
El-Demerdash, E; Elsherbiny, DA; Gerges, SH; Wahdan, SA, 2020
)
2.34
"Pretreatment with diosmin revealed preventive effects on LVH, and all the above mentioned biochemical parameters evaluated in isoproterenol induced myocardial infarcted rats."( Diosmin prevents left ventricular hypertrophy, adenosine triphosphatases dysfunction and electrolyte imbalance in experimentally induced myocardial infarcted rats.
John, B; Ponnian, SMP; Sabarimuthu, SQ, 2017
)
2.22
"Treatment with diosmin-hesperidin improved kidney function and led to a reduction in the excretion of oxidative metabolites."( Sepsis-induced acute kidney injury: kidney protection effects by antioxidants.
Fonseca, CDD; Vasco, CF; Vattimo, MFF; Watanabe, M,
)
0.47
"Pretreatment with diosmin (5 and 10mg/kg body weight) minimized the electrocardiographic changes, decreased the levels of serum cardiac marker enzymes reduced plasma lipid peroxidation and minimized the alterations in the lipid metabolism of isoproterenol-induced myocardial infarcted rats."( Diosmin exhibits anti-hyperlipidemic effects in isoproterenol induced myocardial infarcted rats.
John, B; Queenthy, SS, 2013
)
2.16
"Treatment with diosmin at doses of 50 and 100 mg/kg significantly restored the reduced body weight, elevated blood sugar and lipid profiles."( Protective effect of diosmin against diabetic neuropathy in experimental rats.
Bansal, MK; Dalvi, R; Jain, D; Somani, R; Upganlawar, A, 2014
)
1.06
"Treatment with diosmin (25, 50 and 100 mg/kg body weight) brings back all the above parameters to near normal level, in which 50 mg/kg body weight showed the highest effect than that of other two doses."( Diosmin, a bioflavonoid reverses alterations in blood pressure, nitric oxide, lipid peroxides and antioxidant status in DOCA-salt induced hypertensive rats.
Raja, B; Silambarasan, T, 2012
)
2.16

Toxicity

ExcerptReferenceRelevance
" In animal studies, the safety of Daflon 500 mg is shown by an LD50 (lethal dose 50) of more than 3 g/kg, ie, 180 times the daily therapeutic dose, as well as by the absence of any toxic effect after repeated oral dosing for thirteen and twenty-six weeks, using a dose representing 35 times the daily dosage, in the rate and primate."( Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
Meyer, OC, 1994
)
0.29
" No adverse events, no blood chemistry changes were reported."( Experimental comparative study of the efficacy and side effects of Cissus quadrangularis L. (Vitaceae) to Daflon (Servier) and placebo in the treatment of acute hemorrhoids.
Manmee, C; Panpimanmas, S; Sithipongsri, S; Sukdanon, C, 2010
)
0.36
" There was no significant adverse events in the study groups."( [Safety of use of micronized diosmin at daily doses up to 2000 mg per day].
Staniewska, A, 2016
)
0.73
" No patient showed adverse events."( Effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren®) in addition to complex decongestive therapy on management of breast cancer-related lymphedema.
Bertone, M; Cacchio, A; Centoletti, C; D'Elia, E; De Benedictis, L; Di Carlo, G; Prencipe, R; Taglieri, L, 2019
)
0.77
"Linfadren® in addition to CDT was a safe and effective therapy for reducing BCRL and was better than CDT alone."( Effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren®) in addition to complex decongestive therapy on management of breast cancer-related lymphedema.
Bertone, M; Cacchio, A; Centoletti, C; D'Elia, E; De Benedictis, L; Di Carlo, G; Prencipe, R; Taglieri, L, 2019
)
0.77
"Daflon® is a very effective and safe method for controlling idiopathic epistaxis."( Efficacy and Safety of Daflon® in the Treatment of Idiopathic Epistaxis.
Attia, TM, 2019
)
0.51
" No adverse events were recorded."( Effectiveness and safety of a mixture of diosmin, coumarin and arbutin (Linfadren
Cacchio, A; De Blasis, E; Di Carlo, G; Vincenza, C, 2019
)
0.78
" Thus, we conclude that diosmin may be used along with anti-tubercular drugs (isoniazid and rifampin) in tuberculosis patients to overcome their hepatotoxic adverse effect."( Hepatoprotective potential of diosmin against hepatotoxic effect of isoniazid and rifampin in wistar rats.
Ahmed, RA; Alam, MF; Alqahtani, SS; Alruwaili, MN; Alshahrani, S; Anwer, T; Jali, A; Moni, SS,
)
0.73

Pharmacokinetics

The method was successfully applied to the pharmacokinetic study of diosmin in healthy volunteers following a single oral administration (Daflon) The aim of the current in vivo study was to investigate the pharmacodynamic and clinical activities of 5682 SE.

ExcerptReferenceRelevance
" Analysis of the pharmacokinetic parameters showed that the drug was rapidly absorbed."( Pharmacokinetics and metabolism of oral diosmin in healthy volunteers.
Cova, D; De Angelis, L; Giavarini, F; Palladini, G; Perego, R, 1992
)
0.55
"A randomized double blind multicenter trial was performed to study the pharmacodynamic and clinical activities of 5682 SE, in comparison with diosmin (active principle) well recognised for many years."( Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
Cospite, M; Dominici, A,
)
0.33
" The pharmacodynamic properties of Daflon 500 mg were demonstrated by mercury stress gauge venous occlusion plethysmography during a double-blind placebo-controlled trial in 10 women not presenting any venous disease."( [Study of the pharmacodynamic activity of daflon 500 mg].
Amiel, M; Barbe, R, 1998
)
0.3
" Pharmacokinetic parameters were determined based on non-compartmental model analysis using the computer program RAMKIN."( Influence of diosmin pretreatment on the pharmacokinetics of chlorzoxazone in healthy male volunteers.
Krishna, DR; Nagulu, M; Rajnarayana, K; Srinivas, M; Venkatesham, A, 2008
)
0.72
" Finally, the method was successfully applied to the pharmacokinetic study of diosmin in healthy volunteers following a single oral administration (Daflon)."( Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Azanza, JR; Campanero, MA; Escolar, M; Garcia-Quetglas, E; Perez, G; Sadaba, B, 2010
)
0.88
" These results were confirmed by an in vivo pharmacokinetic study of oral administered fexofenadine (10mg/kg) in rats."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.82
" The aim of the current in vivo study was to investigate the pharmacokinetic profile of a branded micronized diosmin (µSMIN Plus™) compared with plain micronized diosmin in male Sprague-Dawley rats."( Pharmacokinetic Profile of µSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats.
Ciccone, M; Mancinelli, A; Pisano, C; Russo, R; Severino, L; Terruzzi, F, 2015
)
0.87
" Further to test the bioavailability of both the complex and Alvenor⌖ in beagle dogs and compare pharmacokinetic parameters."( Preparation, evaluation and pharmacokinetics of diosmin herbosome in beagle dogs.
Adouani, I; Hang, TJ; Qureshi, AS, 2020
)
0.81

Bioavailability

Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells. Diosmin significantly enhanced oral bioavailability of fexofenadine by the inhibition of P-gp mediated drug efflux during the intestinal absorption.

ExcerptReferenceRelevance
" Pharmacokinetic studies showed that it is well absorbed from the gastrointestinal tract, although is is not clear whether this concerns the unchanged drug or only metabolites."( [Therapeutic effectiveness of flavonoids illustrated by daflon 500 mg].
Hitzenberger, G, 1997
)
0.3
" For each drug, micronization improved their digestive absorption, and consequently their bioavailability and clinical efficacy."( Micronization: a method of improving the bioavailability of poorly soluble drugs.
Chaumeil, JC, 1998
)
0.3
" the use of accelerator mass spectrometry in conjunction with liquid scintillation counting in measurement of bioavailability in a human cross-over study comparing two drug formulations containing trace amounts of radioactivity."( Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting.
Calam, A; Garner, JV; Garner, RC; Gregory, S; Leong, D; Whattam, M, 2002
)
0.54
" Being highly insoluble, DSN bioavailability suffers from high inter-subject variation due to variable degrees of permeation."( Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation.
Abdallah, OY; Elnaggar, YS; Freag, MS, 2013
)
0.63
" The in vivo bioavailability study carried out on rats showed higher initial drug plasma levels and higher AUC values after administration of the nanofibrous drug formulation, compared to the micronized form."( Electrospinning of diosmin from aqueous solutions for improved dissolution and oral absorption.
Berka, P; Doležal, P; Lázníček, M; Stránská, D; Vrbata, P, 2014
)
0.73
"Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
2.26
"Diosmin significantly enhanced the oral bioavailability of fexofenadine by the inhibition of P-gp mediated drug efflux during the intestinal absorption."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
2.26
" For each animal, the following pharmacokinetic parameters were calculated using a non-compartmental analysis: maximum plasma drug concentration (Cmax), time to reach Cmax (Tmax), area under the plasma concentration-time curve (AUC0-last), elimination half-life (t½), and relative oral bioavailability (%F)."( Pharmacokinetic Profile of µSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats.
Ciccone, M; Mancinelli, A; Pisano, C; Russo, R; Severino, L; Terruzzi, F, 2015
)
0.66
" Due to the fact that the anhydrous forms of drugs generally have better bioavailability than the corresponding hydrates, the aim of this study was to analyze the conversion of diosmin monohydrate (DSNM) to anhydrous diosmin (DSNA) that occurs upon heating."( Spectroscopic and structural studies of the diosmin monohydrate and anhydrous diosmin.
Pisklak, DM; Szeleszczuk, Ł; Wawer, I; Zielińska-Pisklak, M, 2017
)
0.91
" It exhibits anti-inflammatory and free radical scavenging properties, but, like many other flavonoids, it is poorly absorbed in the small intestine."( Anti-inflammatory and antiradical effects of a 2% diosmin cream in a human skin organ culture as model.
Boisnic, S; Branchet, MC; Gouhier-Kodas, C; Jabbour, V; Verriere, F, 2018
)
0.73
" Phytocompounds have been proven to enhance osteogenesis via various osteogenic signaling pathways, but its decreased bioavailability and increased renal clearance limit its application."( Osteostimulatory effect of biocomposite scaffold containing phytomolecule diosmin by Integrin/FAK/ERK signaling pathway in mouse mesenchymal stem cells.
Chandran, SV; Selvamurugan, N; Vairamani, M, 2019
)
0.74
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" To overcome this limitation, this study was designed to increase DSN bioavailability and solubility, through its loading on polymeric matrix; hydroxypropyl starch (HPS) and Poly lactide-glycolide-chitin (PLGA/chitin) to prepare Diosmin nanoparticles (DSN-NPs)."( Combating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes.
Allam, AA; El-Banna, M; El-Naggar, ME; Fouda, MMG; Morsy, OM; Om, H; Othman, SI, 2020
)
1.01
"Diosmin is one of the most widely used phlebotonic drugs, but its poor bioavailability has restricted its usage."( Preparation, evaluation and pharmacokinetics of diosmin herbosome in beagle dogs.
Adouani, I; Hang, TJ; Qureshi, AS, 2020
)
2.26
"Many lead compounds fail to reach clinical trials despite being potent because of low bioavailability attributed to their insufficient solubility making solubility a primary and crucial factor in early phase drug discovery."( Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK, 2022
)
0.72
" The alteration of fecal fermentation bacterial profile was analyzed using 16S rRNA sequencing data, while the bioavailability of fiber was indicated by short-chain fatty acid (SCFA) production and metabolism of polyphenols was measured directly by phenolic metabolites."( Flavones interact with fiber to affect fecal bacterial communities in vitro.
Howell, K; Liu, S; Loo, YT; Ng, K; Suleria, H; Zhang, P, 2023
)
0.91

Dosage Studied

Co-administration of diosmin with fexofenadine can reduce the dosage and results in reduced side effects. Daily dosing of Diosmin significantly reduced these markers of liver dysfunction, inflammatory cytokines and apoptosis to near normal levels.

ExcerptRelevanceReference
" The following characteristics emerged: (1) significant improvement of venous capacitance, distensibility, and emptying times, as from the 2nd hour following Daflon 500 mg administration; (2) dose-response relationship, with an optimal dose of 2 tablets per day; (3) rapid onset and long duration of action; (4) significant hemodynamic effect on the venous system, whatever the type of venous insufficiency: organic, functional or gestational."( Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
Amiel, M; Barbe, R; Duchene Marullaz, P,
)
0.13
" There was a greater effect at the higher dosage than at the lower one."( The effects of diosmin (a benzo-pyrone) upon some high-protein oedemas: lung contusion, and burn and lymphoedema of rat legs.
Casley-Smith, JR, 1985
)
0.62
" Daflon 500 mg was administered at the dosage of three tablets bid the first four days and two tablets bid the following three days."( Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
Cospite, M, 1994
)
0.29
" In animal studies, the safety of Daflon 500 mg is shown by an LD50 (lethal dose 50) of more than 3 g/kg, ie, 180 times the daily therapeutic dose, as well as by the absence of any toxic effect after repeated oral dosing for thirteen and twenty-six weeks, using a dose representing 35 times the daily dosage, in the rate and primate."( Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
Meyer, OC, 1994
)
0.29
" Further studies with a higher dosage could confirm the beneficial activity of this drug in secondary lymphedema."( Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer).
Février, B; Pecking, AP; Pillion, G; Wargon, C, 1997
)
0.3
" For examining the modifying effects of 'initiation' treatment of test compounds, groups of animals were fed the diets containing 1000 ppm diosmin and 1000 ppm hesperidin, and the diet containing both compounds (900 ppm diosmin and 100 ppm hesperidin) for 13 weeks, starting 7 days before the MNAN dosing and then switched to the basal diet."( Modulation of N-methyl-N-amylnitrosamine-induced rat oesophageal tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in combination.
Fukutani, K; Hara, A; Kakumoto, M; Kawabata, K; Makita, H; Mori, H; Ogawa, H; Satoh, K; Sumida, T; Tanaka, T, 1997
)
0.71
" The methods were applied for determination of the diosmin and/or hesperidin in Buchu leaves and pharmaceutical dosage forms (three tablets)."( Improved LC methods for the determination of diosmin and/or hesperidin in plant extracts and pharmaceutical formulations.
El-Domiaty, MM; El-Shafae, AM, 2001
)
0.82
" In randomized trials, 60 days of therapy with Daflon at a dosage of 500 mg 2 tablets daily was effective, in addition to elastic compression, in accelerating venous ulcer healing."( Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg.
Bergan, JJ,
)
0.13
" On the basis of results it seems that high dosage of the diosmin-hesperidin mixture induces slight changes in the Cu, Zn, Mn and Fe content of the liver, however it may decrease the scavenger capacity and the activity of SOD when applied either alone or together with thioacetamide."( Effects of citrus flavonoids on redox homeostasis of toxin-injured liver in rat.
Blázovics, A; Fehér, E; Kurucz, T; Lugasi, A; Pallai, Z; Rapavi, E; Székely, E; Szentmihályi, K, 2006
)
0.58
" Co-administration of diosmin with fexofenadine can reduce the dosage and results in reduced side effects of fexofenadine."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
1.13
"0%) subjects strictly adhered to the physician's prescription and stopped taking the drug without violation of the regimen and dosing of diosmin."( [Multicentre observational study of Phlebodia 600 in treatment of patients with CEAP class C0-C3 chronic venous diseases].
Belentsov, SM; Iashkin, MN; Katel'nitskaia, OV; Kletskin, AÉ; Kudykin, MN; Sevost'ianova, KS; Stoĭko, IM; Suchkov, IA; Talibov, OB; Tolstikhin, VI,
)
0.33
" There are also no data confirming the benefits of daily dosage of 3000 mg per day of micronized fraction of flavonoids compared with 1800 mg of purified diosmin per day for treatment of acute hemorrhoids."( [Common sense of diosmin administration in combined treatment of hemorrhoids].
Arkharov, AV; Bashankaev, BN; Wexner, SD,
)
0.67
" However, daily dosing of diosmin significantly reduced these markers of liver dysfunction, inflammatory cytokines and apoptosis to near normal levels."( Hepatoprotective potential of diosmin against hepatotoxic effect of isoniazid and rifampin in wistar rats.
Ahmed, RA; Alam, MF; Alqahtani, SS; Alruwaili, MN; Alshahrani, S; Anwer, T; Jali, A; Moni, SS,
)
0.72
" In our study, patients were administered a daily dosage of 2 × 600 mg of diosmin for 3 months, and we evaluated several factors associated with oxygen management, angiogenesis, and inflammation using biochemical assays."( Effect of Diosmin on Selected Parameters of Oxygen Homeostasis.
Dresler, S; Feldo, M; Płachno, BJ; Samborski, D; Sowa, I; Sowa, P; Wójciak, M, 2023
)
1.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements3

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Baywood International Natural Balance Diosmin -- 60 TabletsBaywood InternationalVitamins & SupplementsDiosmin2024-11-29 10:47:42
Flora CircuVein -- 60 Vegetarian CapsulesFloraVitamins & SupplementsDiosmin, Hesperidin2024-11-29 10:47:42
Ginsana Venastat® Leg Vein Health -- 60 CapsulesGinsanaVitamins & SupplementsDiosmin2024-11-29 10:47:42

Roles (2)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
glycosyloxyflavoneA member of the class of flavones having one or more glycosyl residues attached at unspecified positions.
rutinoside
disaccharide derivativeA carbohydrate derivative that is formally obtained from a disaccharide.
monomethoxyflavoneAny methoxyflavone with a single methoxy substituent.
dihydroxyflavanoneAny hydroxyflavanone carrying two hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.48130.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency19.95260.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency27.54040.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency38.90180.002541.796015,848.9004AID1347395
ATAD5 protein, partialHomo sapiens (human)Potency5.80240.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID743255
PPM1D proteinHomo sapiens (human)Potency32.99930.00529.466132.9993AID1347411
GLI family zinc finger 3Homo sapiens (human)Potency23.71010.000714.592883.7951AID1259369
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency12.58930.01237.983543.2770AID1346984
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.84930.001530.607315,848.9004AID1224849
aryl hydrocarbon receptorHomo sapiens (human)Potency22.40470.000723.06741,258.9301AID743085; AID743122
Histone H2A.xCricetulus griseus (Chinese hamster)Potency49.19400.039147.5451146.8240AID1224845
DNA polymerase betaHomo sapiens (human)Potency25.11890.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency56.23410.133725.412989.1251AID588795
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency18.04440.000627.21521,122.0200AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency79.43280.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency41.22300.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency2.81840.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.56230.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency18.88760.031622.3146100.0000AID720501
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
Interferon betaHomo sapiens (human)Potency32.99930.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)IC50 (µMol)3.89000.00090.97819.8200AID1719951
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)10.14000.00312.16029.6000AID1515260
Aurora kinase BHomo sapiens (human)IC50 (µMol)9.14000.00030.96349.8000AID1801097
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (119)

Processvia Protein(s)Taxonomy
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cortical actin cytoskeleton organizationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
toll-like receptor 3 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
Fc-epsilon receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
T cell receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stress-activated MAPK cascadeInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein maturationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
interleukin-1-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein localization to plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of establishment of endothelial barrierInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of bicellular tight junction assemblyInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
membrane raftInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (125)

Assay IDTitleYearJournalArticle
AID1801097Aurora B Kinase Assay from Article 10.1111/cbdd.12445: \\Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.\\2015Chemical biology & drug design, May, Volume: 85, Issue:5
Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1657132Antiinflammatory activity against Swiss mouse model of LPS-induced inflammatory pain assessed as decrease in IL6 level in peritoneal cavity at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by ELISA2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1566635Antidiabetic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in blood glucose AUC at 100 mg/kg, po for 14 days followed by overnight fasting and later orally treated with maltose for 60 mins and measured after 120 mins by 2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID386545Stability in hank's balanced salt solution at 15 uM after 24 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID386549Apparent permeability from basolateral to apical side in human Caco-2 cells assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1657117Antiinflammatory activity against Swiss mouse model of LPS-induced peritonitis assessed as decrease in leukocyte recruitment in peritoneal cavity by measuring reduction in mononuclear cells at 30 to 100 mg/kg, po pretreated for 1 hr followed by LPS-stimul2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1657128Antiinflammatory activity against Swiss mouse model of LPS-induced inflammatory pain assessed as decrease in IL1beta level in hind paw skin at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by ELISA2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1719951Inhibition of IKKbeta (unknown origin) assessed as substrate phosphorylation using IkappaBalpha as substrate incubated for 1 hr in presence of ATP by chip-based fluorescence assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Small molecule inhibitors of IκB kinase β: A chip-based screening and molecular docking simulation.
AID1566633Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as serum triglyceride level at 100 mg/kg, po for 4 weeks (Rvb = 3.08 +/- 0.84 mM)2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1566637Antidiabetic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in postprandial glucose level at 50 mg/kg, po for 2 hrs by glucometer analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1657119Antiinflammatory activity against Swiss mouse model of LPS-induced peritonitis assessed as decrease in total ROS level at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by H2DCF-DA staining based confocal microscopic2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1566626Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in serum total cholesterol level at 100 mg/kg, po for 4 weeks relative to diabetic control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1866041Lipophilicity, logP of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1657135Inhibition of NFkappaB in Swiss mouse peritoneal exudates model of LPS-induced inflammatory pain assessed as ratio of phosphorylated NFkappaB p65 at (Ser536 residue) to total NFkappaB p65 at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1657127Antiinflammatory activity against Swiss mouse model of LPS-induced inflammatory pain assessed as decrease in TNFalpha level in hind paw skin at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by ELISA2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1719072Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 03-01, Volume: 35Flavonoids from Sophora alopecuroides L. improve palmitate-induced insulin resistance by inhibiting PTP1B activity in vitro.
AID386543Stability in hank's balanced salt solution at 15 uM after 120 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1657118Antiinflammatory activity against Swiss mouse model of LPS-induced peritonitis assessed as decrease in leukocyte recruitment in peritoneal cavity by measuring reduction in polymorphonuclear at 30 to 100 mg/kg, po pretreated for 1 hr followed by LPS-stimul2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1566625Antidiabetic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as increase in glucose tolerance at 50 to 100 mg/kg, po for 13 days followed by overnight fasting and later orally treated with glucose for 60 mins and measured after 120 mi2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1566616Inhibition of PTP1B in CHOK1 cells assessed as increase in phosphorylation of AKT at Ser473 residue at 20 uM measured after 48 hrs by Western blot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1657124Antioxidant activity in Swiss mouse model of LPS-induced inflammatory pain assessed as increase in GSH level in hind paw skin at mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by colorimetric based assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID581111Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.
AID1566628Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in serum triglyceride level at 50 mg/kg, po for 4 weeks relative to diabetic control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID379055Cytotoxicity against human monocytes assessed as depletion of cellular LDH activity1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1657133Inhibition of NFkappaB in Swiss mouse peritoneal exudates model of LPS-induced inflammatory pain at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by Alexa Fluor 647 staining based immunofluorescence assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID734905Lipophilicity, log P of the compound2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Enhancement of the water solubility of flavone glycosides by disruption of molecular planarity of the aglycone moiety.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1566622Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate measured after 30 mins by spectrophotometry analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1657121Antiinflammatory activity against Swiss mouse model of LPS-induced peritonitis assessed as decrease in NBT-positive leukocytes in peritoneal exudate at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by light microsco2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1566617Inhibition of PTP1B in CHOK1 cells assessed as increase in phosphorylation of GSK-3beta at Ser9 residue at 20 uM measured after 48 hrs by Western blot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1566621Increase in insulin secretion in high glucose-treated rat INS-1 cells preincubated with compound and 40 mM glucose for 48 hrs followed by stimulation with KRB buffer containing 5 to 30 mM glucose for 60 mins and measured by ELISA2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1657122Antioxidant activity in Swiss mouse model of LPS-induced inflammatory pain assessed as decrease in superoxide production in hind paw skin at mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by colorimetric based NBT assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID293299Antioxidant activity in BALB/c mouse BM cells assessed as inhibition of ROS production2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID1566623Antidiabetic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in fasting blood glucose level at 50 to 100 mg/kg, po administered for 4 weeks by glucometric analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1566632Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as serum triglyceride level at 50 mg/kg, po for 4 weeks (Rvb = 3.08 +/- 0.84 mM)2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1566631Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as serum total cholesterol level at 100 mg/kg, po for 4 weeks (Rvb = 9.75 +/-0.11 mM)2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID386544Stability in hank's balanced salt solution at 15 uM after 180 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1566620Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 10 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1566636Decrease in PTP1B protein expression in CHOK1 cells at 20 uM measured after 48 hrs by Western blot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID379054Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1866020Thermodynamic aqueous solubility of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1657120Antiinflammatory activity against Swiss mouse model of LPS-induced peritonitis assessed as decrease in superoxide anion production in peritoneal wash at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by NBT based spe2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1657111Analgesic activity in Swiss mouse model of LPS-induced inflammatory pain assessed as reduction in mechanical hyperalgesia at 30 to 100 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 1 to 5 hrs by Von Frey test2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1616108Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID1566634Antidiabetic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in blood glucose AUC at 50 mg/kg, po for 14 days followed by overnight fasting and later orally treated with maltose for 60 mins and measured after 120 mins by O2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1566629Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in serum triglyceride level at 100 mg/kg, po for 4 weeks relative to diabetic control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID386551Apparent permeability across PAMPA membrane assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1657123Antioxidant activity in Swiss mouse model of LPS-induced inflammatory pain assessed as reduction in lipid peroxidation in hind paw skin at mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by colorimetric based TBARS assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID386547Apparent permeability from apical to basolateral side in human Caco-2 cells assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1657134Inhibition of NFkappaB in Swiss mouse peritoneal exudates model of LPS-induced inflammatory pain assessed as reduction area of colocalization between phosphorylated NFkappaB p65 and DAPI at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and 2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1566624Antidiabetic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as decrease in blood glucose AUC at 50 to 100 mg/kg, po administered for 4 weeks by glucometric analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1566619Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 5 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1657125Antioxidant activity in Swiss mouse model of LPS-induced inflammatory pain assessed as ABTS radical scavenging activity in hind paw skin at mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by colorimetric based assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1657129Antiinflammatory activity against Swiss mouse model of LPS-induced inflammatory pain assessed as decrease in IL6 level in hind paw skin at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by ELISA2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1566618Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 1 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID734906Aqueous solubility of the compound in water after 2 days by HPLC analysis2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Enhancement of the water solubility of flavone glycosides by disruption of molecular planarity of the aglycone moiety.
AID1657116Antiinflammatory activity against Swiss mouse model of LPS-induced peritonitis assessed as decrease in leukocyte recruitment in peritoneal cavity by measuring reduction in total leukocytes at 30 to 100 mg/kg, po pretreated for 1 hr followed by LPS-stimula2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1566614Increase in glucose consumption in human HepG2 cells assessed as glucose concentration in the medium treated at 0.4 to 10 uM after incubating cells in the medium containing glucose measured after 24 hrs by glucose oxidase method2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1657112Analgesic activity in Swiss mouse model of LPS-induced inflammatory pain assessed as reduction in thermal hyperalgesia at 30 to 100 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 1 to 5 hrs by hot plate technique2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1657130Antiinflammatory activity against Swiss mouse model of LPS-induced inflammatory pain assessed as decrease in TNFalpha level in peritoneal cavity at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by ELISA2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1657126Antioxidant activity in Swiss mouse model of LPS-induced inflammatory pain assessed as total ferric ion reducing activity in hind paw skin at mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by colorimetric based FRAP ass2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1566630Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as serum total cholesterol level at 50 mg/kg, po for 4 weeks (Rvb = 9.75 +/-0.11 mM)2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID293297Antioxidant activity assessed as DPPH radical scavenging activity after 20 min2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID1515260Inhibition of LSD1 (unknown origin) by fluorescence assay2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
AID1657113Analgesic activity in LPS-induced Swiss mouse assessed as increase in right/left paw ratio at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 1 to 5 hrs by static weight bearing assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID386542Stability in hank's balanced salt solution at 15 uM after 60 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID386541Stability in hank's balanced salt solution at 15 uM after 20 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID293298Antioxidant activity assessed as inhibition of superoxide production by xanthine/xanthine oxidase method2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID1657114Analgesic activity in LPS-induced Swiss mouse assessed as decrease in neutrophil recruitment in hind paw skin by measuring MPO activity at 10 to 100 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 5 hrs by colorimetric assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1657115Analgesic activity in LPS-induced C57BL/6 mouse harboring LysM-eGFP assessed as decrease in neutrophil recruitment in hind paw skin by measuring fluorescence at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 5 hrs by confo2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID1657131Antiinflammatory activity against Swiss mouse model of LPS-induced inflammatory pain assessed as decrease in IL1beta level in peritoneal cavity at 30 mg/kg, po pretreated for 1 hr followed by LPS-stimulation and measured after 3 hrs by ELISA2020Journal of natural products, 04-24, Volume: 83, Issue:4
Diosmin Treats Lipopolysaccharide-Induced Inflammatory Pain and Peritonitis by Blocking NF-κB Activation in Mice.
AID720501qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds2012PloS one, , Volume: 7, Issue:10
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (470)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (5.32)18.7374
1990's91 (19.36)18.2507
2000's98 (20.85)29.6817
2010's168 (35.74)24.3611
2020's88 (18.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.93 (24.57)
Research Supply Index6.47 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index181.30 (26.88)
Search Engine Supply Index3.88 (0.95)

This Compound (55.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials106 (19.63%)5.53%
Reviews59 (10.93%)6.00%
Case Studies9 (1.67%)4.05%
Observational6 (1.11%)0.25%
Other360 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]